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Abstract
Raynaud’s phenomenon (RP) is a clinical consequence of recurrent vasospasm of the 
small arteries and arterioles of the fingers and toes provoked by cold and emotional 
stress. RP is classified into two categories, i.e., primary and secondary RP. Primary RP 
is an isolated finding in the absence of an underlying pathology, while secondary RP 
is a syndrome in the context of another disease. The patients with primary RP have a 
younger age at onset, sparing of the thumb, and benign course without development of 
digital ulcers. Contrarily, secondary RP is characterized with later age of onset above 30 
years, thumb involvement, and more severe course with possible development of trophic 
changes. In these cases, a focused, complaint-directed history and physical examination 
aim to reveal clinical symptoms and findings that confirm the presence of an underlying 
disorder, e.g., connective tissue disease (CTD) or other pathology. Together with clinical 
examination, laboratory, immunological, and capillaroscopic assessments facilitate the 
internal differential diagnosis of secondary RP. The capillaroscopic examination should 
be performed in all patients with symptoms of RP even in those cases without signs of 
systemic rheumatic disease, because the abnormal capillaroscopic picture inherits a high 
positive predictive value for the development of CTD.
Keywords: Raynaud’s phenomenon, primary, secondary, peripheral vascular 
syndromes, capillaroscopy
1. Definition
The term “Raynaud’s phenomenon” (RP) originates from the name of the French physician 
Maurice Raynaud, who described transient digital ischemia provoked by cold exposure and 
hypothesized that the changes are associated with exaggerated response of the central nervous 
system. Currently, the term “RP” defines the clinical consequence of recurrent vasospasm of 
the small arteries, arterioles, and arteriovenous shunts of the fingers and toes provoked by 
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cold and emotional stress [1]. Other acral parts, e.g., the nose, lips, and ears, may be also 
affected. It manifests usually in three phases, ischemia, asphyxia, and reactive hyperemia, 
during which skin color changes occur consecutively from white to blue and red. A character-
istic feature of RP is the clear demarcation between the affected and unaffected area.
2. Diagnosis of Raynaud’s phenomenon
The diagnosis of RP is clinical and is based on direct observation of the vasospastic attacks [1]. 
Photographs that document the vasospastic attacks could also be used to confirm the history 
[2]. In routine clinical practice, it is not necessary to perform a cold provocation test to make a 
definite diagnosis of RP [1].
Observation of at least biphasic color changes is necessary for the diagnosis, as pallor and 
cyanosis are considered to be the most important signs. In a recent international consensus 
for the diagnosis of RP (Maverakis et al. [3]), a three-step approach for the diagnosis of RP 
has been suggested. The first two steps include asking more general questions: (I) a question 
about unusual sensitivity of the fingers to cold and (II) a question about “occurrence of bipha-
sic color changes during the vasospastic episodes (white and blue).” Finally, during step III, 
the physician calculates the disease score by asking seven questions to the patient ((1) epi-
sodes are triggered by factors other than cold, i.e., emotional stress; (2) episodes involve both 
hands even if they are asynchronous or asymmetric; (3) numbness and paresthesias accom-
pany vasospastic attacks; (4) well-demarcated border between the affected and unaffected 
skin; (5) photographs provided by the patient; (6) vasospastic episodes that affect other body 
parts such as the nose, ears, feet, and areolas; (7) occurrence of triphasic color changes during 
vasospastic attacks, e.g., white, blue, and red). If the score from step III is ≥3, the patient is 
diagnosed with RP [3].
3. Classification of Raynaud’s phenomenon
RP is classified into two categories, i.e., primary and RP [1, 4, 5, 6].
Primary RP is an isolated finding in the absence of an underlying pathology, while second-
ary RP is a syndrome in the context of another disease. The patients with primary RP have a 
younger age of onset (below 30 years), sparing of the thumb, and benign course without the 
development of digital ulcers [4, 6, 7].
On the contrary, secondary RP is characterized with later age of onset above 30 years, thumb 
involvement, and a more severe course with possible development of trophic changes in some 
cases (digital ulcerations, digital necrosis) [4, 6, 7]. In these cases, a focused, complaint directed 
history and physical examination aim to reveal clinical symptoms and findings that confirm 
the presence of an underlying disease, e.g., connective tissue disease (CTD) or other disorders. 
The secondary RP is a characteristic feature in a number of rheumatic diseases. In systemic 
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sclerosis (SSc)/scleroderma, it is with the highest frequency of approximately 95% [8]. RP 
could also be a sign in a spectrum of nonrheumatic pathology that also should be recognized 
and properly differentiated by the rheumatologists in routine clinical practice (Table 1) [8–14].
Together with clinical examination, laboratory, immunological, and capillaroscopic assess-
ments facilitate the internal differential diagnosis of secondary RP and reveal the definite final 
diagnosis.
Nailfold capillaroscopy is a noninvasive, easy-to-perform method for diagnosis and differential 
diagnosis of patients with primary and secondary RP in rheumatic diseases (particularly the 
scleroderma-spectrum disorders), which is of crucial importance because of the different severity, 
prognosis, and therapeutic approach. Normal capillaroscopic pattern is an established diagnostic 
criterion for the diagnosis of primary RP. In addition, it has been found that capillaroscopic pat-
tern in healthy individuals is constant for long periods of time. During the follow-up of patients 
with RP, it has been found that the appearance of abnormal capillaroscopic findings inherits a 
positive predictive value of 47% for the development of CTD that is higher as compared with the 
predictive value of the positive antinuclear autoantibody (ANA) test (30%) [15]. The appearance 
of giant capillaries is the earliest capillaroscopic sign of microangiopathy and represents a local 
response to tissue hypoxia. In RP patients, nailfold capillaroscopic analysis should be performed 
every 6 months and more often if new alarming symptoms appear. The capillaroscopic examina-
tion should be performed in all patients with symptoms of RP even in those cases without clini-
cal and laboratory signs of systemic rheumatic disease, because the abnormal capillaroscopic 
picture inherits a high positive predictive value for the development of CTD.
Systemic sclerosis
Mixed connective tissue disease
Undifferentiated connective tissue disease
Systemic lupus erythematosus
Dermatomyositis, polymyositis
Sjögren syndrome
Rheumatoid arthritis
Systemic vasculitides-Buerger disease, Takayasu arteritis, polyarteritis nodosa, granulomatosis with polyangiitis, etc.
Fibromyalgia
Cryoglobulinemia
Drug-induced Raynaud’s phenomenon—beta-blockers, cytotoxic drugs, vinblastine, bleomycin, interferon, etc.
Paraneoplastic Raynaud’s phenomenon—associated with solid tumors and hematological malignancies
Endocrine disorders—hypothyroidism
Neurologic disorders—carpal tunnel syndrome
Table 1. Differential diagnosis of secondary Raynaud’s phenomenon in rheumatologic practice.
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4. Pathogenesis of Raynaud’s phenomenon
The vasospasm in primary RP is reversible, while the secondary Raynaud’s phenomenon in 
systemic sclerosis is associated with endothelial injury and subsequent structural abnormali-
ties that lead to tissue damage.
Adrenergic alpha-2 receptors that are more important than alpha-1 receptors in the control of 
vasoconstriction of digital arteries are suggested to be abnormal in RP. The receptor subtype 
alpha-2c is found to predominate in the vascular smooth muscle cells of distal cutaneous ves-
sels [16, 17]. Alpha-2c adrenergic receptors are not active at room temperature. In response 
to cold exposure, they are activated as a result from translocation from the Golgi complex 
to the plasmatic membrane [18, 19]. Estrogens also activate alpha-2c adrenoreceptors that 
could explain the predominance of primary RP in females and the increased severity of symp-
toms between menarche and menopause [20]. An association between enhanced contractile 
response to alpha-2c agonists and increased protein tyrosine kinase activity and tyrosine 
phosphorylation has been found. Greater intracellular tyrosine phosphorylation in response 
to cooling (31°C) has been found in arterioles in both primary and secondary RP patients vs. 
controls using immunofluorescence and an antiphosphotyrosine antibody [21, 22].
The endothelium controls blood vessel tone via production of vasodilators (nitric oxide 
(NO), prostacyclin) and vasoconstrictors (endothelin-1, angiotensin). Endothelial damage in 
secondary RP in SSc leads to disbalance between vasodilators and vasoconstrictors [10, 23]. 
In SSc-related RP, increased level of asymmetric dimethylarginine (an endogenous NO 
synthesis inhibitor produced by endothelial cells) was observed. Elevated plasma level of 
endothelin-1 was found in SSc as compared with primary RP [24]. Increased expression of 
endothelin-1 in the skin of SSc patients was also detected [25]. Besides its properties of vaso-
constrictor, it has been confirmed that endothelin-1 promotes fibrosis in scleroderma patients 
[26]. In SSc, endothelial injury represents a key pathogenic step that mediates the processes of 
inflammation, thrombus formation, and fibrosis [23]. The role of endothelin-1 in pathogenesis 
of primary RP has also been implicated in some studies, but the evidence is weaker in compari-
son with SSc [10, 27].
Calcitonin gene-related peptide (CGRP) is a neuropeptide and a potent vasodilator produced 
by peripheral sensory nerves. In RP (primary and secondary RP in SSc), especially the second-
ary forms in SSc, a reduction in the number of CGRP immunoreactive neurons in the skin was 
found [28].
5. Primary Raynaud’s phenomenon
In a recent systematic literature review, the prevalence of primary RP is reported to vary from 
1.6 to 7.2% (calculated pooled prevalence—4.85%) [29]. As mentioned above, the primary RP 
is characterized with early age of onset, mainly at puberty. This classic type of presentation 
predominates in female patients with family history. Despite the fact that the age of onset is 
considered to be a discriminating factor between primary and secondary RP, it should be inter-
preted individually as primary RP with late onset (above the age of 40) is also possible [30].
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5.1. Diagnosis of primary Raynaud’s phenomenon
Wide application in clinical practice have the diagnostic criteria of Le Roy and Medsger (1992) 
that encompass the following findings:
1. Vasospastic attacks precipitated by cold or emotional stress
2. Symmetric attacks
3. Absence of digital ulcerations or gangrenes
4. Normal erythrocyte sedimentation rate
5. Negative test for ANA
6. Normal capillaroscopic picture [31]
Maverakis et al. published an international consensus for diagnosis of primary RP, which 
includes the following criteria: (1) normal capillaroscopy; (2) negative physical examination 
for findings suggestive of secondary causes such as ulcerations, tissue necrosis or gangrene, 
sclerodactyly, calcinosis, or skin fibrosis; (3) no history of existing CTD; and (4) negative or 
low titer ANA as low titer is considered (1:40) by indirect immunofluorescence. In the newly 
accepted criteria of Maverakis et al., the presence of normal erythrocyte sedimentation rate is 
not included, and negative test for ANA is not required [3] (Table 2). Normal capillaroscopic 
pattern exists in both sets of criteria.
In primary RP, capillary morphology and capillary density are normal. Slightly enlarged cap-
illary diameters could be found [32–34].
6. Secondary Raynaud’s phenomenon
Older age of onset, thumb involvement, severe course with trophic alterations of the fingers 
(digital ulcers, digital necrotic lesions), clinical features suggestive of autoimmune disease, 
positive autoantibodies, and abnormal capillaroscopic findings are characteristic features of 
secondary RP in rheumatic diseases [4, 6, 7].
6.1. Raynaud’s phenomenon in systemic sclerosis
RP is one of the most common symptoms in SSc with frequency of about 95% [8]. It is usually 
the initial clinical feature that appears years before other disease symptoms. SSc-related RP 
is severe and often complicates with development of digital ulcers. The capillaroscopic pat-
tern in SSc is specific and is characterized with the presence of dilated and giant capillaries, 
hemorrhages, avascular areas, and neoangiogenic capillaries. It has been described by Maricq 
et al. and is termed “scleroderma” type capillaroscopic pattern, which is a reference capil-
laroscopic pattern in rheumatology. Maricq et al. also observed components of this pattern 
in diseases from the scope of scleroderma-spectrum disorders, e.g., mixed connective tissue 
disease (MCTD), undifferentiated connective tissue disease (UCTD), and dermatomyositis 
(DM)—the so-called “scleroderma-like” pattern [35–37].
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Figure 1. “Scleroderma type” capillaroscopic pattern in SSc (1) “early” phase, there is a single giant capillary loop and a 
single hemorrhage; (2) “active” phase, magnification 200×.
Cutolo et al. [38] described three phases of capillaroscopic changes in SSc:
I. An “early” phase—appearance of few dilated and/or giant capillaries and few hemor-
rhages. In this phase, the distribution is relatively preserved without loss of capillaries.
II. An “active” phase—the changes in this phase include a higher number of giant capillaries 
and hemorrhages, a moderate loss of capillaries, slight derangement, and, in some cases, 
diffuse pericapillary edema (Figure 1).
III. A “late” phase—it is characterized with extensive avascular areas, severe capillary 
derangement, and bushy and ramified capillaries [38].
“Scleroderma” type capillaroscopic pattern is found in the majority of SSc patients (about 90%). 
Maricq et al. detected “scleroderma” pattern in 82–95% of SSc patients [36, 37]. In an own study, 
“scleroderma” pattern of the hands was detected in 97.2% (35/36) of SSc patients [34, 39, 40].
In addition, it has been found that a number of patients with a definite diagnosis of SSc (those 
with sclerodactyly, telangiectasia, subcutaneous calcinosis, esophageal dysmotility, etc.) do 
not fulfill the ACR (American College of Rheumatology) classification criteria for the disease 
(1980). An abnormal “scleroderma” type capillaroscopic pattern was found in these cases [41]. 
Le Roy and Medsger [31] Maverakis et al. [3]
1. Vasospastic attacks precipitated by cold or 
emotional stress
2. Symmetric attacks
3. Absence of digital ulcerations or gangrenes
4. Normal erythrocyte sedimentation rate
5. Negative test for ANA
6. Normal capillaroscopic picture
1. Normal capillaroscopy
2. Negative physical examination for findings suggestive of secondary 
causes (e.g., ulcerations, tissue necrosis or gangrene, sclerodactyly, 
calcinosis, or skin fibrosis)
3. No history of existing CTD
4. Negative or low titer ANA (e.g., 1:40 by indirect immunofluorescence)
Table 2. Diagnostic criteria for primary Raynaud’s phenomenon (Le Roy and Medsger [31]; Maverakis et al. [3]).
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For establishing the diagnosis of SSc according to the ACR criteria (1980), the presence of the 
major criterion (skin thickening proximal to metacarpophalangeal joints of the hands) or two 
minor criteria ((1) sclerodactyly, (2) fingertip pitting scars, (3) bibasilar pulmonary fibrosis) is 
required [42]. These criteria have been proposed prior to the discovery of SSc-related autoanti-
bodies and the characteristic capillaroscopic findings, which both had been found to improve 
the early diagnosis of SSc [43, 44]. Thus, Le Roy and Medsger suggested patients with RP and 
“scleroderma” type capillaroscopic changes or positive SSc-related autoantibodies to be diag-
nosed as “prescleroderma” or limited SSc even if other disease symptoms are absent [45]. The 
multicenter project VEDOSS (Very Early Diagnosis of Systemic Sclerosis) resulted in the new 
classification criteria for SSc (European League Against Rheumatism (EULAR)/ACR, 2013), 
which aim to detect SSc in early stages. In the new EULAR/ACR classification criteria, RP is 
scored with 3 points (1), the abnormal capillaroscopic pattern with 2 points (2), and presence 
of SSc-related autoantibodies (anticentromere, anti-topoisomerase I (anti-Scl-70), anti-RNA 
polymerase) with 3 points (maximum score for the immunologic criterion is 3) (3). The other 
criteria (overall 8 criteria) are as follows: telangiectasia (2 points) (4); fingertip lesions (digital 
tip ulcers - 2 points or fingertip pitting scars - 3 points), only the higher score is counted (5); 
pulmonary arterial hypertension and/or interstitial lung disease are scored with 2 points (6); 
skin thickening of the fingers (puffy fingers - score 2; sclerodactyly of the fingers - score 4), 
only the higher score is counted (7); skin thickening of both hands proximal to the metacar-
pophalangeal joints is scored with 9 points (8). A score ≥ 9 is necessary for a definite diagnosis 
of SSc [46, 47].
6.2. Raynaud’s phenomenon in mixed connective tissue disease
MCTD combines symptoms of systemic lupus erythematosus (SLE), SSc, polymyositis (PM)/DM, 
arthritis, and the presence of a specific immunologic marker—anti-U1 RNP (an antibody 
against extractable nuclear antigen)—the latter being an obligatory classification criterion for 
the disease [48]. RP is met in 85% of patients with MCTD [8] and is the most common ini-
tial symptom [49]. Currently, the classification criteria for MCTD used in clinical practice 
are suggested by different author groups and not by professional organizations (criteria of 
Alarcon-Segovia, Kasukawa, Sharp, Kahn). RP is included in all of them because of its high 
frequency in MCTD [50]. Of note, the “SSc-like” capillaroscopic changes could be observed 
in a significantly lower proportion of MCTD patients in comparison with SSc. Maricq et al. 
have observed “SSc-like” pattern in 54% of cases in the examined group of 26 MCTD patients 
[36]. Bergman et al. detected “SSc-like” pattern in 50% (4/8) of the cases [51] and de Holanda 
Mafaldo Diógenes et al. in 65–71.5% [52]. Granier et al. observed a similar frequency of 
“scleroderma-like” capillaroscopic pattern—63.6% [53].
6.3. Raynaud’s phenomenon in undifferentiated connective tissue disease
In UCTD patients, there are different symptoms of systemic rheumatic disease, but there is no 
full set of criteria of a well-defined rheumatic disorder. RP is a frequent symptom that may be 
observed in about 80% of the patients with UCTD. In evolution, a proportion of these patients 
(1/4–1/3) develop a distinct rheumatic disease, the most frequent being SSc, SLE, rheuma-
toid arthritis (RA), and Sjögren syndrome, but the majority of cases remain in a clinically 
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and laboratory stable condition in the scope of the term “UCTD.” In UCTD, the frequency 
of “scleroderma-like pattern” is lower as compared with SSc (13.8%, Nagy et al. [41]; 38%, 
Lambova et al.) [34, 54]. The presence of “scleroderma-like” capillaroscopic pattern in patients 
with UCTD is considered to be a reliable predictive factor for the development of SSc [41].
6.4. Raynaud’s phenomenon in systemic lupus erythematosus
The prevalence of RP in SLE is between 10 and 45% [8]. Although in a proportion of cases with 
SLE peripheral vessel is affected by vasculitis, RP usually tends to have a benign course with-
out the development of digital ulcers or necrosis [9]. Microvascular capillaroscopic changes 
in SLE are less specific vs. those in scleroderma-spectrum disorders. However, several capil-
laroscopic features have been noted in SLE that are termed “SLE” type capillaroscopic pattern 
[51, 53, 55], which includes the presence of elongated [53, 56] and dilated capillary loops, 
tortuous and meandering capillaries [55], and prominent subpapillary plexus [53, 56]. 
“Scleroderma-like” capillaroscopic pattern is a rare finding in SLE with frequency varying 
between 2 and 15% [36, 41, 51, 56, 57]. An association between “scleroderma-like” capilla-
roscopic pattern and the presence of RP and anti-U1 RNP antibody has been observed that 
is suggested to be in the context of a possible subclinical overlap syndrome with SSc [57]. 
In an own study of 30 SLE patients, RP was found in 73% of cases, and “scleroderma-like” 
capillaroscopic pattern in 13.3% of the patients (4/30). Such changes were observed in patients 
with high immunological activity, two of whom were with active vasculitis of peripheral 
vessels and two with secondary RP. They did not exhibit signs of overlap with SSc or other 
CTD. Anti-RNP antibody was positive in a single case in a patient with symptoms of second-
ary RP without peripheral vessel vasculitis, while in the other three cases with “scleroderma-
like” pattern, this immunological marker was negative [34, 54]. Thus, it could be concluded 
that “scleroderma-like” capillaroscopic pattern could be found in SLE patients with high 
immunological activity, both in cases with active vasculitis of peripheral vessels and only 
with symptoms of secondary RP but without evidence for overlap with SSc or other CTD.
6.5. Raynaud’s phenomenon in dermatomyositis and polymyositis
RP occurs in about 20% of DM/PM patients [8]. Digital gangrenes of the hands are usually not 
observed. When such changes are evident, the presence of neoplasm should be suspected. RP 
is characteristic for the antisynthetase syndrome, which is a subset of myositis characterized 
with positive anti-Jo-1 antibodies (against histidyl-tRNA synthetase), interstitial lung disease, 
nonerosive symmetric polyarthritis in small joints, and cracking and fissuring of the skin of 
the fingers (“mechanic’s hands”) [58]. In a part of the cases with DM, “scleroderma-like “cap-
illaroscopic findings could be observed [35]. Although the capillaroscopic changes in DM 
and SSc are usually indistinguishable, it is suggested that bushy and branching capillaries 
could be found more frequently in DM [59]. The frequency of “SSc-like” pattern detected by 
Bergman et al. in 11 patients with DM was 63.6% [51].
6.6. Raynaud’s phenomenon in rheumatoid arthritis
The prevalence of RP in RA varies between 3 and 17% (2.7%, Carrol et al., North Australia [60]; 
4.6%, Grassi et al., Italy [61]; and 17.2%, Saraux et al., France) [62]. In 31 RA patients, Redisch 
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et al. observed the following capillaroscopic changes: presence of elongated capillary loops, 
increased capillary tortuosity, and prominent subpapillary plexus. A “SSc-like” pattern was 
not detected in RA [55]. Nagy et al. also did not observe “SSc-like” pattern in a group of 14 
patients with RA [41].
Of note, in an own study that included higher number of patients with RA (n = 62) with and 
without RP, a “SSc-like” pattern was observed in 14.5% (9/62; 2 males and 7 females). In one 
of the nine cases with such capillaroscopic changes, an overlap syndrome (RA overlap to 
SLE) with secondary RP and secondary vasculitis of peripheral vessels was evident. While in 
the rest eight out of nine patients, no overlap with other CTD was present. All RA patients 
with “SSc-like” capillaroscopic pattern (9/9) exhibited symptoms of secondary RP, and 2/9 a 
secondary vasculitis of peripheral vessels, respectively. Our results suggest that “SSc-like” 
capillaroscopic pattern could be observed in RA patients with secondary RP and with vasculi-
tis of peripheral vessels although with low frequency. However, its presence is not mandatory 
in the context of overlap syndromes [34, 63].
6.7. Paraneoplastic Raynaud’s phenomenon
RP may be a paraneoplastic symptom. When RP is newly appeared with late onset after the 
age of 60, it may also be an indicator for an underlying malignancy. Ischemia of the fingers has 
been reported in patients with carcinomas of the breast, the stomach, and the esophagus as 
well as in patients with oncohematologic disease (multiple myeloma, thrombocythemia, etc.). 
In a part of the cases, paraneoplastic RP is caused by secretion of vasoactive substances by 
the tumor cells and the respective immune response of the body, while in others like multiple 
myeloma and thrombocytopenia, it is associated with increased blood viscosity [64, 65]. We 
have not observed differences between microvascular changes in paraneoplastic rheumatic 
conditions in comparison with the respective idiopathic rheumatic diseases [66].
6.8. Raynaud’s phenomenon in fibromyalgia
Fibromyalgia is an idiopathic, chronic, musculoskeletal, pain syndrome characterized with 
diffuse pain and presence of multiple tender points [67]. Primary fibromyalgia is an isolated 
disorder, while secondary fibromyalgia could be observed in different rheumatic diseases, 
e.g., RA, SLE, Sjögren syndrome, etc. [68]. RP is met in both primary and secondary fibro-
myalgia. The frequency of RP in fibromyalgia patients is about 17–30% [69, 70]. In an own 
study that included 26 patients with primary fibromyalgia, the most frequent capillaroscopic 
finding was the presence of dilated capillary loops analogous to primary RP. Capillaroscopic 
signs of microangiopathy were not detected [71].
7. Differential diagnosis of RP with other vascular acrosyndromes
Acrocyanosis represents painless bluish discoloration in the distal body parts, most commonly 
in the hands and feet and less frequently in the face that are affected symmetrically. In acrocy-
anosis, the bluish skin discoloration is a persistent finding that is aggravated by cold exposure 
and frequently is associated with local hyperhidrosis and edema of the hands and feet. In the 
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absence of an accompanying cause, acrocyanosis is considered primary (idiopathic, essential) 
that is suggested to be a benign condition and typically does not require specific treatment. It 
does not evolve into CTD or other diseases and may spontaneously resolve. secondary acro-
cyanosis is a manifestation of other major diseases. Both acrocyanosis and RP are influenced 
by cold exposure and emotional stress, but in acrocyanosis, there is relative persistence of 
skin color changes, symmetry, and absence of paroxysmal pallor. Of note, RP may occur con-
comitantly with acrocyanosis. In addition, the persistence of acrocyanosis is also relative, and 
it may also demonstrate improvement in the summer as well as in horizontal and elevated 
position of the hand vs. dependent position [72].
Perniosis (chilblain) is a localized cutaneous inflammatory reaction in response to acute or 
repetitive exposure to damp cold above the freezing point. The skin lesions are edematous 
plaques that may be purple or red and are often painful or pruritic. In severe cases, ulceration, 
superinfection, and scarring may occur. Fingers and toes are most commonly affected although 
other areas, e.g., nose, ears, buttocks, or thighs, could also be involved. Primary and secondary 
forms are recognized. Secondary perniosis could be associated with a variety of underlying 
pathological conditions such as hepatitis, autoimmune disease, and cryopathies [73].
Erythromelalgia is characterized with episodic, symmetric, and painful hyperthermia and ery-
thema of hands and feet. Contrary to RP, erythromelalgia is provoked by exposure to heat 
or physical exercise. Primary and secondary forms are also recognized, primary being a rare 
hereditary disease that manifests in children and young people, while secondary is met in the 
context of myeloproliferative disorders, diabetes, and SLE and during drug treatment with 
calcium channel blockers (CCBs) [74].
8. Treatment
8.1. Primary RP
The mild forms of primary RP are controlled by non-pharmacological measures, e.g., patient 
education in avoiding exposure to cold, use of warm clothes and gloves, smoking cessation, using 
protective devices in working with vibration. Caffeine consumption, administration of vasocon-
strictors such as beta-blockers, and use of interferons should be avoided when possible [9].
Dihydropyridine-type CCBs have been the treatment of choice for patients with both primary 
and secondary RP for many years. They have proven efficacy for reduction of the severity and 
frequency of ischemic attacks in primary RP and secondary RP in SSc. Diltiazem (benzothi-
azepine class CCBs) could also be used in RP. It is administered at a dose of 30–120 mg three 
times daily orally. Verapamil (diphenylalkylamine class of CCBs) does not possess therapeu-
tic effect in RP patients [75–77]. Nifedipine is the best studied and the most often used drug 
from dihydropyridine class CCBs. It is used at a dose of 10–40 mg twice daily orally. Other 
dihydropyridines commonly used in patients with RP are felodipine (2.5–10 mg twice daily 
orally) and amlodipine (5–10 mg daily orally) [1, 9]. Dihydropyridine class CCBs are vasodila-
tors with direct effect on vascular smooth muscles. They are indicated for the treatment of 
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arterial hypertension and stable angina, and some of them are also officially approved for 
vasospastic angina [78]. In RP patients, their use is off-label. Side effects of CCBs are common, 
e.g., flushing, hypotension, dizziness, headache, tachycardia, ankle edema, constipation, etc. 
Slow-release forms are better tolerated and preferred in clinical practice [1]. Pregnancy is 
a contraindication for administration of CCBs—a fact that deserves attention considering 
the high prevalence of primary RP in young women. This patient category requires specific 
instructions, and those women at childbearing age who plan conception or do not use effec-
tive contraception should not receive CCBs. Alternative, better-tolerated therapeutic options 
are often preferred in primary RP considering the milder clinical course and good prognosis 
of this condition as well as the side effects of CCBs.
Pentoxifylline inhibits phosphodiesterase and elevates cyclic adenosine monophosphate 
(cAMP) levels in polymorphonuclear leukocytes and other cells [79]. It exerts beneficial effects 
on microcirculation via improvement of blood fluidity, especially influencing erythrocyte 
flexibility [80]. Its maximal daily dose is 1200 mg (400 mg three times daily or 600 mg twice 
daily orally). It is not proven to be effective in severe forms of RP [1].
Therapeutic effect of Ginkgo biloba has been studied in patients with primary RP in double-
blind, placebo-controlled trial. Significant reduction in the number of attacks has been 
observed in the group treated with high dose of Ginkgo biloba (360 mg daily) as compared with 
the placebo group (56 vs. 27%). It is suggested that Ginkgo biloba together with its vasodilator 
properties possesses also antiplatelet and radical scavenging effects [81].
8.2. Secondary RP in systemic sclerosis
EULAR recommends dihydropyridine-type CCBs as first-line therapy for RP in SSc [82]. A meta-
analysis, including 8 randomized clinical trials (7 with nifedipine and 1 with nicardipine) with 
109 SSc patients, indicates that dihydropyridine-type CCBs reduce the frequency and severity 
of ischemic attacks in SSc-related RP [77]. Apart from their effect to reduce the severity and 
frequency of vasospastic attacks, it has been demonstrated that CCBs lead to healing of digital 
ulcers [83]. In SSc with severe RP and/or those who do not respond satisfactorily to CCBs, 
phosphodiesterase-5 enzyme inhibitors are recommended (EULAR recommendation) [82]. NO is 
the main endothelium-derived vasodilator and an inhibitor of platelet activation and vascular 
smooth muscle proliferation. Its synthesis is regulated by the family of NO synthases, and 
its effect is mediated via cyclic guanosine monophosphate (cGMP). The intracellular concen-
tration of cGMP is regulated by phosphodiesterases, which rapidly degrade cGMP in vivo 
[84]. A meta-analysis, including six randomized clinical trials (two with sildenafil, three with 
tadalafil, and one with vardenafil), demonstrated that phosphodiesterase-5 inhibitors have a 
significant effect on frequency and duration of RP attacks. Efficacy on healing of digital ulcers 
has been also reported. The therapeutic regimens used were as follows: sildenafil 50 mg twice 
daily or 200 mg once daily, tadalafil 20 mg daily or 20 mg on alternate days, and vardenafil 
10 mg twice daily. The dosage regimens depend on half-lives of the different drugs that are 
3–5 h for sildenafil and vardenafil (administered twice daily apart from modified-release 
sildenafil that is administered as a single dose) and about 18 h for tadalafil (administered 
once daily or on alternate days) [85]. Side effects during treatment with phosphodiesterase-5 
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inhibitors included different forms of vasomotor reactions, myalgias, allergic reaction, chest 
pain, dyspepsia, nasal stuffiness, and visual abnormalities. Considering long-term experience 
and good safety profile, EULAR experts recommend CCBs as first-line therapy for SSc-related 
RP and phosphodiesterase-5 inhibitors for SSc with severe RP and/or in cases with insufficient 
effect from the treatment with CCBs [82].
Intravenous iloprost possesses proven efficacy for reduction of the frequency and severity 
of SSc-related RP. Considering costs and feasibility, it is recommended after failure of oral 
therapies (CCBs and phosphodiesterase-5 inhibitors). Intravenous iloprost is also efficacious 
in the treatment of digital ulcers in SSc that is proved in randomized, placebo-controlled clini-
cal trials [86, 87]. However, the need for hospitalization, the prolonged intravenous infusion 
(6 hours at the dose of 0.5–2 ng/kg/min), side effects, and high price are limiting factors for 
the administration of iloprost. Adverse effects include headache, nausea, vomiting, diarrhea, 
myalgia, arthralgia, chills, fever, arrhythmia, hypotension, chest pain (especially in patients 
with coronary heart disease), erythema, and pain at the infusion site. Thus, concomitant 
pathology should be assessed and hemodynamic parameters of the patients closely observed, 
e.g., blood pressure, heart rate, and pulse at the beginning and at every increase of the infusion 
rate. The risk for orthostatic hypotension should be also considered. Apart from its properties 
as a vasodilator, iloprost inhibits platelet aggregation, leukocyte chemotaxis, and adhesion 
to the endothelium. Iloprost also downregulates the expression of adhesion molecules on 
endothelial cells and phagocytes and enhances fibrinolytic activity [86–88].
In addition, in the most recent EULAR recommendation, fluoxetine (a serotonin-specific reup-
take inhibitor and antidepressant) is suggested as an option in SSc-related RP despite the 
scarce published evidence [82]. In a small study that included 26 patients with primary RP 
and 27 with SSc-related RP, fluoxetine (20 mg daily) showed superior efficacy vs. nifedip-
ine (40 mg daily). Observed side effects of fluoxetine were apathy, lethargy, and impaired 
concentration [89]. Despite the relatively low quality of published evidence, EULAR experts 
suggest fluoxetine as a useful alternative for treatment of SSc-related RP, especially in SSc 
patients who do not tolerate or fail to respond to vasodilators [82].
In SSc patients, in whom RP has complicated with digital ulcers, EULAR experts recommend 
intravenous iloprost and phosphodiesterase-5 inhibitors for treatment of digital ulcers and bosentan 
(endothelin receptor antagonist) for reduction of the number of new digital ulcers [82].
9. Prognosis
Being a first symptom in a number of CTD, the presence of RP requires regular follow-up that 
includes clinical, laboratory, immunological, and capillaroscopic assessment. The appearance 
of pathological capillaroscopic picture inherits a higher positive predictive value (47%) for 
the development of CTD vs. the predictive value of the positive ANA test (30%) [15]. Thus, 
nailfold capillaroscopy is the key investigation for monitoring RP patients. The interval of 
follow-up is 6 months, because a longer period of time is usually necessary for the develop-
ment of morphological capillaroscopic changes, but this period may be shorter in cases with 
newly appeared alarming symptoms.
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